Media Kit - assets.contentstack.io · Media Kit. SYNTHEGO’S FULL STACK | About Us| APPROACH AND...
7
Media Kit
Transcript of Media Kit - assets.contentstack.io · Media Kit. SYNTHEGO’S FULL STACK | About Us| APPROACH AND...
Media Kit
SYNTHEGO’S FULL STACK
| About Us | APPROACH AND IMPACT | ENGINEER BIOLOGY | INNOVATION TIMELINE | LEADERS & INVESTORS
Transforming Our Understanding of Human Biology to Accelerate Life Sciences Research and Development
Synthego is a genome engineering company accelerating life science research and development in the pursuit of improved human health.
With its foundations in engineering disciplines, the company vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology into Synthego’s“full stack” platform to accelerate applications in target discovery and validation, genetic pathway analysis, and engineering biological therapies.
Leveraging machine learning, automation, and gene editing to tackle the complexity of biology with engineering rigor to enable agile life science research and development from discovery through clinical introduction.
Engineered Cells ResearchCRISPR Innovations, Tools & Technologies, Cell Diversity
Functional BiologyAssay Development, Disease Modeling
Research Hardware + Systems EngineeringCustom Hardware for Automation of High Throughput Editing
Research ChemistryCustom Chemistry, Scale and Purity
BioinformaticsData Analysis Hypothesis Generation Modeling
Research SoftwareComprehensive Data Architecture
All Top 40Academic Institutions
18 Out of 20 Fortune 500 Biopharmaceuticals
Company Info
Headquartered inSan Francisco Bay Area
5 sites~250 Employees
Advisory team of science & tech
innovation leadersfrom top medical
research institutions and Fortune 500
companies
Thousands of Customers Include:
CRISPR(precision)
Machine Learning(predictability)
Automation(scalability)+ + =
| ABOUT US | Approach and Impact | ENGINEER BIOLOGY | INNOVATION TIMELINE | LEADERS & INVESTORS
Genome Engineering Audience
>50,000CRISPR GENE EDITS
80%AVERAGEEDITING
EFFICIENCY
>425PUBLICATIONS
CITING SYNTHEGO
CUTTING-EDGERESEARCHIN OVER
45 Countries
At the forefront of innovation, Synthegoaddresses the unmet
need for transformative effectiveness and agility in the life sciences research and development by unlocking the full
potential of genome
engineering.
“By making scientific advancements more accessible, Synthego is poised to have an enormous impact on researchers in life sciences and will transform the industry…”
Jennifer Doudna
CRISPR Co-InventorSynthego Advisory Board Member
Synthego is a featured voice in award winning documentary from executive producer Dan Rather.
“Grounds the wild story of CRISPR with a healthy dose of humanity.”
– Engadget
Andrew Witty
CEO Optum, Former CEO GSKSynthego Advisory Board Member
“Synthego’s vision for automating biological research will revolutionize the industry by accelerating application development and enabling machine learning based insights.”
“Synthego has brought an energetic and innovative approach to the genome editing field. Moreover, the engineering background they bring to the field means that they have developed solutions to problems that biologists and geneticists might not have come up with.”
Matt Porteus
Cell Therapy PioneerStanford Professor, ClinicianSynthego Advisory Board Member
Era of Biology Yields Discoveries to DesignNext Generation Medicines
| ABOUT US | APPROACH AND IMPACT | Engineer Biology | INNOVATION TIMELINE | LEADERS & INVESTORS
‘Transformative Science in a Pandemic Era’
‘Synthego’s New Products Give Scientists Access to Edited Genetic Material’
‘Biology Will Be the Next Great Computing Platform’
CompanyFounded
Our Full Stack Genome Engineering Innovation Timeline
Accelerate R&D
| ABOUT US | APPROACH AND IMPACT | ENGINEER BIOLOGY | Innovation Timeline | LEADERS & INVESTORS
SyntheticsgRNA Kit
EngineeredCells
ArrayedScreeningLibraries
CRISPR-EditediPS Cells
GMPsgRNA
LaunchedGold Standard forGenome Editing
Launched Unprecedented
Access to CRISPR
PresentedSynthetic sgRNA
Discovery Libraries
Introduced High Throughput iPSCfor Cell Models
Extending intoClinical Setting with
Synthetic sgRNA
Reduce Costs and Wait Times by 5x
Optimized Methods and Guaranteed,
CRISPR Done for You
Enable Screening in Clinically
Relevant Cells
Validate and Study Your Biology
Accelerate to Clinical
Introduction
EVALUATEMODELDISCOVERENGINEERTRANSFORM
2012 2016 2018 2019 Present
Our Leaders and Investors
Committed to making gene therapy more accessible for the millions who suffer from genetic disorders, Paul led the creation and commercialization of the company’s world-class genome engineering offerings. Prior to Synthego, Paul was the lead digital designer for the Falcon 9 rocket and Dragon spacecraft at SpaceX. His innovator portfolio also includes a mobile software company, and the world’s smallest electron microscope for DNA sequencing. Under Paul's leadership, Synthego has grown to a 250+ employee company with 100+ million in funding and multi-million-dollar revenue from multiple products sold across 45 countries.
| ABOUT US | APPROACH AND IMPACT | ENGINEER BIOLOGY | INNOVATION TIMELINE | Leaders & Investors
>$250 MillionCumulative Funding
Paul DabrowskiCO-FOUNDER AND CEO
| View My Profile
Jason SteinerCHIEF STRATEGY OFFICER
| View My Profile
Forrest Baringer-JonesCHIEF FINANCIAL OFFICER
| View My Profile
Michael NemzekCHIEF COMMERCIAL OFFICER
| View My Profile
John TanCHIEF OPERATING OFFICER
| View My Profile
Robert ”Bob” DeansCHIEF SCIENTIFIC OFFICER
| View My Profile
